IEC 2023 | A digital biomarker to support decision making in a first seizure clinic

Phil Tittensor, RNMH, MSc, The Royal Wolverhampton NHS Trust, Wolverhampton, UK, introduces the PRISTINE trial, investigating the value of a digital biomarker to support diagnostic decision making in first seizure clinics. BioEP is a support tool that analyzes EEG for the presence of data features and brain network markers that are known to be elevated in people with epilepsy. The digital biomarker applies mathematical modeling to EEG data in order to predict the likelihood of seizures and produce a risk score. BioEP can detect subtle network differences indicative of epilepsy even in the absence of observable epileptiform abnormalities. Mr Tittensor is leading the first prospective clinical study using this technology. BioEP will be applied to the EEGs of individuals attending the clinic with a suspected first seizure. The consultant nurse will rate the probability that a patient had an epileptic seizure and the likelihood of recurrence based on clinical history and EEG alone, and then again after receiving the risk score. This interview took place at the International Epilepsy Congress 2023 in Dublin, Ireland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.